Aim 1 – Discover the genetic factors behind the most frequent, life-threatening and permanently disabling ADRs. The lab collaborates with clinicians and other research teams to identify patients with serious ADRs. We search for gene variants that might be associated with ADRs. Promising gene variants are then validated against cohorts from other biobanks to confirm whether similar results appear. Once they have determined gene variants implicated in an ADR, the Ross Lab seeks to discover the specific role these gene variants play. This requires functional validation and mechanistic studies.
Aim 2 – Develop genome-targeted therapeutics to repair the DNA of genetically defined diseases. Dr. Ross developed an innovative gene therapy to treat a genetic disease by inserting functional copies of a gene into patient cells. We are working to develop and optimize novel therapeutics that specifically repair malfunctioning genes within a patient using recently discovered approaches to target and repair disease-causing mutations.
Aim 3 – Implement findings into clinical practice
Research conducted in the Ross Lab provides critical evidence to support the introduction of new tests at the bedside that can predict and avoid a dangerous ADR. We are pursuing:
- Developing ADR-predictive tests
- Developing ADR prediction models
- Publishing clinical practice guidelines
- Developing ADR apps for use at point of care
- Advocating for drug label changes where appropriate
- Pre-clinical development of new therapeutics